Adaptimmune Therapeutics plc (ADAP)

Market Cap	64.18M
Revenue (ttm)	178.03M
Net Income (ttm)	-70.81M
Shares Out	257.23M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	989,538
Open	0.2400
Previous Close	0.2339
Day's Range	0.2350 - 0.2509
52-Week Range	0.1950 - 1.4800
Beta	2.84
Analysts	Strong Buy
Price Target	1.83 (+633.47%)
Earnings Date	May 14, 2025

About ADAP

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2015
• Employees: 506
• Stock Exchange: NASDAQ
• Ticker Symbol: ADAP
• Website: https://www.adaptimmune.com

Financial Performance

In 2024, Adaptimmune Therapeutics's revenue was $178.03 million, an increase of 195.34% compared to the previous year's $60.28 million. Losses were -$70.81 million, -37.81% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for ADAP stock is "Strong Buy." The 12-month stock price forecast is $1.83, which is an increase of 633.47% from the latest price.

Price Target

$1.83

(633.47% upside)

Analyst Consensus: Strong Buy